Skye Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $60.73M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | After market close | – | $-0.36 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | – | $-0.32 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | $-0.44 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | $-0.28 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
Press releases
Announcements Skye Bioscience filed with the SEC
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
14 August, 2026 Definitive Transaction Agreement between Skye Bioscience and Redx Pharma NASDAQ: SKYE Redx: Private UK Company
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Skye / Redx Conference Call
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases February 2026 Nasdaq: SKYE
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Skye Bioscience Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Skye Bioscience Reports Topline CBeyond TM Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Results of operations · EX-99.1 to Form 8-K
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Executive or director change · Other events · EX-99.1 to Form 8-K
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Skye Concentrates Strategy and Clinical Development Focus on
Other events · EX-99.1 to Form 8-K
SKYE BIOSCIENCE, INC. AND SUBSIDIARIES
Regulation FD disclosure · EX-99.1 to Form 8-K
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
SKYE BIOSCIENCE, INC. AND SUBSIDIARIES
Other events · EX-99.1 to Form 8-K
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Skye Bioscience Reverse Stock Split to be Effective on September 8th
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Transaction & Overview Q3 2023 +
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Skye Financing and Bird Rock Bio: Pre-recorded Call Script
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
Auditor change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K